New Treatment of Alopecia Areata

Abstract: Alopecia areata is believed to be an autoimmune disease resulting from a breach in the immune privilege of the hair follicles causing non scarring hair loss. Methods: our study included 40 patients from may 2019 to july 2022 diagnosed clinically, dermatoscopically and pathologically as alopecia areata Data were enrolled from department of dermatology and venereology, Al-Hussein hospital.

For each patient the following will be done : History taking including ( age, sex, disease duration, family history, history of drug intake, smoking and history of any associated disease ). All patients will give a written, informed consent for induction. Basic photographs will be taken to assess site, size (by cm), number, Extent of the patch using D5300 camera with lens (18-55). Patients will be subjected to 3 session of trichloroacetic acid (TCA) 35% one month apart. serial photographs and dermoscopic examination every month will be done and patient will be score. Efficacy will be assessed using prognostic scoring system for density, pigmentation, and texture of growing hair. histopathological examination will be done before the first session and one month after third session.

regrowth of vellus hair, regrowth of sparse pigmented terminal hair, regrowth of terminal hair with patches of alopecia and regrowth of terminal hair on scalp.

appearance of lymphocytes around hair follicle, appearance of new blood vessels and size of thickness of hair follicles

Inclusion Criteria: Alopecia areata multilocularis and alopecia totalis. Age from 16-60 years old. Ophiasis pattern alopecia areata. Exclusion Criteria: Age less than 16 and more than 60years old. Alopecia areata of the face. Patient under treatment.